Regulatory Hurdles Threaten Larimar Therapeutics’ Nomlabofusp BLA and Commercial Launch Timeline
at www.tipranks.com (Tue, 17-Nov 1:00 AM)
Larimar Therapeutics GAAP EPS of -$0.29 beats by $0.06
at seekingalpha.com (Mon, 16-Nov 7:17 AM)